Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor
about
Pseudovirions as vehicles for the delivery of siRNARetargeting Strategies for Oncolytic Herpes Simplex VirusesOncolytic virotherapy using herpes simplex virus: how far have we come?A herpes simplex virus vector system for expression of complex cellular cDNA librariesInsertion of a ligand to HER2 in gB retargets HSV tropism and obviates the need for activation of the other entry glycoproteins.Herpes simplex virus oncolytic therapy for pediatric malignanciesOncolytic viruses: From bench to bedside with a focus on safety.Herpesvirus vectors for therapy of brain tumors.Bispecific adapter-mediated retargeting of a receptor-restricted HSV-1 vector to CEA-bearing tumor cells.Cross talk among the glycoproteins involved in herpes simplex virus entry and fusion: the interaction between gB and gH/gL does not necessarily require gD.The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its ReceptorsSeparation of receptor-binding and profusogenic domains of glycoprotein D of herpes simplex virus 1 into distinct interacting proteins.Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade gliomaPediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children.Designing Herpes Viruses as Oncolytics.Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapyEffective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virusReprogrammed viruses as cancer therapeutics: targeted, armed and shielded.Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells.Displacement of the C terminus of herpes simplex virus gD is sufficient to expose the fusion-activating interfaces on gD.Specific targeting of human interleukin (IL)-13 receptor α2-positive cells with lentiviral vectors displaying IL-13.The potential application of a transcriptionally regulated oncolytic herpes simplex virus for human cancer therapy.Oncolytic viral therapy of malignant gliomaInduction of conformational changes at the N-terminus of herpes simplex virus glycoprotein D upon binding to HVEM and nectin-1Rethinking herpes simplex virus: the way to oncolytic agents.A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.Retargeting of herpes simplex virus (HSV) vectors.Mechanism of HSV infection through soluble adapter-mediated virus bridging to the EGF receptor.Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2.A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection.Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity.Targeting human glioma cells using HSV-1 amplicon peptide display vector.Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.Simultaneous Insertion of Two Ligands in gD for Cultivation of Oncolytic Herpes Simplex Viruses in Noncancer Cells and Retargeting to Cancer Receptors.HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic VirusesHerpes Simplex Virus Vectors for Gene Transfer to the Central Nervous System
P2860
Q24634231-C6DB6066-7DA1-463B-A4C3-7B5BB167E46AQ26765439-981D8C9D-A2AE-4E8F-9C8F-AD516DDACD26Q26862461-9DCD60C3-7C5F-474F-91E0-6482471FC937Q33576519-3472A1C2-5AEB-4A01-B506-299A12CAA36BQ33621028-F49FAF47-C0D6-4B05-BBE7-D6D6CCA9E4A9Q33713824-BBFC5833-8FA8-4CBE-A743-C7AAE7407711Q34044071-E724B55E-38E0-47DC-A461-4530E06AF0CDQ34091990-7176E792-EBFC-4D09-A7E2-76C834A83AB0Q34621654-C4FABD30-2F46-433E-BA82-7016B578BEF8Q34995805-8458E81D-2552-4E97-B003-011F7F006715Q35638350-D3EE6755-7855-48E9-9CEA-C5AF90D351F7Q35676817-386A3452-EA0E-4320-AFA3-F06F178CE818Q35939421-5A5E184C-55DE-40FF-A71F-2AA02197A5E8Q36109704-166EFD0A-1393-4ECC-A1E8-B5D10282244FQ36142487-F3FFE2D4-E462-4908-BDE8-68B6F6B6319AQ36544212-8D513331-1265-4846-95B5-886331C89FF9Q36644898-F934670D-2FF7-4F3E-B84E-4219AE8215DBQ36659325-5327B6C3-D3D9-4494-803E-F3FB86408A39Q37191007-34D3FCCA-652E-4D2D-85CC-1740D8C2D612Q37198935-250CF376-C737-435F-B527-2183719B75F6Q37336556-5B518C14-0E3C-427E-9248-B242E73C2505Q37358531-FE2D59EE-718D-4420-A0AB-043B9550F031Q37459624-A6FB1173-08B5-4DB6-95D4-2FBF5BAAB52BQ37533665-887C07BE-5651-4AEA-9270-DF544B48923FQ37691560-AF73596E-33A9-4655-9C02-F3D1B25F2DA6Q37882608-A59B9064-CC6A-4A98-80B1-27A9214A6CD1Q38714321-631EEC7D-0087-4E01-A779-2B7496F81510Q38791776-3B9CCAD1-E05A-4BB3-AF87-3B196AE2639BQ38950892-CA2DF268-DC7A-40E4-B318-98152D32AF55Q39580061-A0BE2D3B-4733-4362-AD24-E9FC18D2963CQ39953338-27F09CB6-A260-46C6-9E5C-44E92ECF623FQ41806893-633B0375-53CA-4E43-A4C1-AE2BA8BE5569Q42133458-A454F151-91F2-4DF2-9853-879F82571286Q45888950-BD8E579C-5E94-44B1-9BC6-151FCCB300AFQ47562626-93A7F473-9591-4B6D-9C45-555BDE3DAC2CQ47562637-D3B440DA-B14F-49BB-B4AB-475325F1728BQ56378150-ADA7844D-79F8-485F-A04A-40075AEA66D7Q58779571-26D0BB6D-35D9-4ECC-B96D-7DAB9393A3C3
P2860
Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13alpha2 receptor
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Construction and properties of ...... y via the IL-13alpha2 receptor
@ast
Construction and properties of ...... y via the IL-13alpha2 receptor
@en
Construction and properties of ...... y via the IL-13alpha2 receptor
@nl
type
label
Construction and properties of ...... y via the IL-13alpha2 receptor
@ast
Construction and properties of ...... y via the IL-13alpha2 receptor
@en
Construction and properties of ...... y via the IL-13alpha2 receptor
@nl
prefLabel
Construction and properties of ...... y via the IL-13alpha2 receptor
@ast
Construction and properties of ...... y via the IL-13alpha2 receptor
@en
Construction and properties of ...... y via the IL-13alpha2 receptor
@nl
P2860
P356
P1476
Construction and properties of ...... y via the IL-13alpha2 receptor
@en
P2860
P304
P356
10.1073/PNAS.0601258103
P407
P577
2006-03-22T00:00:00Z